T2 Biosystems (NASDAQ: TTOO)
FY 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2023-12-20 | ||||||
REV |
FY 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2023-11-09 | ||||||
REV |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of T2 Biosystems (NASDAQ: TTOO) through any online brokerage.
Other companies in T2 Biosystems’s space includes: Vincerx Pharma (NASDAQ:VINC), Aeglea BioTherapeutics (NASDAQ:AGLE), Cellectar Biosciences (NASDAQ:CLRB), Brooklyn (NASDAQ:BTX) and Larimar Therapeutics (NASDAQ:LRMR).
The latest price target for T2 Biosystems (NASDAQ: TTOO) was reported by Cantor Fitzgerald on Friday, August 12, 2022. The analyst firm set a price target for 4.00 expecting TTOO to rise to within 12 months (a possible 1974.69% upside). 50 analyst firms have reported ratings in the last year.
The stock price for T2 Biosystems (NASDAQ: TTOO) is $0.1928 last updated August 12, 2022, 8:00 PM UTC.
The next T2 Biosystems (TTOO) dividend date is projected to be Thursday, September 1, 2022.
T2 Biosystems’s FY earnings are confirmed for Wednesday, December 20, 2023.
There is no upcoming split for T2 Biosystems.
T2 Biosystems is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.